Literature DB >> 17276947

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.

Mark H Stoler1, Philip E Castle, Diane Solomon, Mark Schiffman.   

Abstract

Mesh：

Year:  2007        PMID： 17276947     DOI： 10.1309/RNF3C01JKADQCLKP

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


× No keyword cloud information.
  36 in total

1.  Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.

Authors:  Philip E Castle; Erin C Gutierrez; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Laurence M Vaughan; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

2.  Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort.

Authors:  Brandon J LaMere; Janet Kornegay; Barbara Fetterman; Mark Sadorra; Jen Shieh; Philip E Castle
Journal:  J Virol Methods       Date:  2007-07-27       Impact factor: 2.014

3.  Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.

Authors:  F Bottari; M Sideri; C Gulmini; S Igidbashian; A Tricca; C Casadio; S Carinelli; S Boveri; D Ejegod; J Bonde; M T Sandri
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

Review 4.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

6.  Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Authors:  Samuel Ratnam; Francois Coutlee; Dan Fontaine; James Bentley; Nicholas Escott; Prafull Ghatage; Veeresh Gadag; Glen Holloway; Elias Bartellas; Nick Kum; Christopher Giede; Adrian Lear
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

7.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

8.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

9.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

10.  Validation of human papillomavirus genotyping by signature DNA sequence analysis.

Authors:  Sin Hang Lee; Veronica S Vigliotti; Jessica S Vigliotti; Suri Pappu
Journal:  BMC Clin Pathol       Date:  2009-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.